The FreeStyle Libre GCM can monitor your glucose levels without needing a blood sample. Here’s what you should know about how to use it, where you can get it, and how it compares to other glucose ...

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...

Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Abbott issued a medical device correction for some ...

Abbott Laboratories ABT recently presented late-breaking data on its FreeStyle Libre system at the American Diabetes Association’s (“ADA”) 81st Scientific Sessions. Data showed that this continuous ...

Abbott's FreeStyle Libre Flash glucose monitoring system--Courtesy of Abbott Diabetes care at Abbott Laboratories ($ABT) has returned to sales growth as ex-U.S. sales ...

Abbott Laboratories’ ABT next-generation FreeStyle Libre 3 system was recently approved by the FDA for diabetes patients aged four years and older. The FreeStyle Libre 3 system will be priced ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

Despite the flood of apocalyptic warnings from COVID-19 testmakers who kicked off 2022 with stark predictions of dwindling diagnostic sales and, therefore, major hits to their year-over-year results, ...